Rigel Pharmaceuticals | RIGL - Gross Profit On Sales


Rigel Pharmaceuticals reported $28.49M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Agenus USD 34.2M 4.61M Dec/2025
Amgen USD 6.89B 415M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Celldex Therapeutics USD 121K 609K Dec/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Ligand Pharmaceuticals USD 48.45M 8.22M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Veracyte USD 101.16M 814K Mar/2026